Galectin-8 Protein Regulates CD44v Localization and Limits STAT3 Signaling in Gastric Metaplasia
A new study using genetically modified mice found that galectin-8, a binding protein, controls where CD44v receptors are positioned on cell membranes and suppresses STAT3 signaling in gastric metaplasia. Gastric metaplasia is a precancerous condition where stomach lining cells transform into a different cell type. The findings suggest that low galectin-8 levels may contribute to worse outcomes in gastric cancer by allowing excessive STAT3 signaling.
Researchers compared galectin-8 knockout mice to normal mice using a chemically induced model of gastric spasmolytic polypeptide expressing metaplasia (SPEM), a precancerous stomach condition. They discovered that galectin-8 is required for proper membrane localization of CD44v, a receptor implicated in metaplasia and cancer, and that galectin-8 acts as a brake on CD44-mediated STAT3 signaling. Mice lacking galectin-8 showed increased nuclear phosphorylated STAT3 in metaplastic glands compared to wild-type controls, indicating heightened signaling activity. The study suggests a physical interaction between galectin-8 and CD44v through glycan binding. These mechanistic findings may explain the clinical observation that low galectin-8 expression correlates with poor prognosis in gastric cancer patients.
What's missing
The study does not discuss whether findings in this murine model translate to human gastric tissue, potential therapeutic implications of restoring galectin-8 function, or whether galectin-8 levels can be therapeutically modulated. The paper also does not address whether other galectins compensate for galectin-8 loss or whether the findings apply to other cancer types.
What different sources said
- bioRxivCenter
Galectin-8 Modulates Membrane CD44v Localization and Tempers STAT3 Signaling in Gastric Metaplasia
Related
Study Identifies Galectin-3's Role in Gastric Metaplasia Development Through Cathartocytosis
Researchers found that galectin-3, a protein upregulated in precancerous tissue changes, facilitates a cellular process called cathartocytosis that promotes the development of spasmolytic polypeptide expressing metaplasia (SPEM) in the stomach. Galectin-3 is abnormally expressed alongside sulfated mucins in high-risk precancerous conditions like Barrett's esophagus and intestinal metaplasia. The findings suggest galectin-3 may represent a therapeutic target for preventing progression from normal tissue to metaplastic and potentially cancerous states.
Study reveals spermatogonial stem cell clones don't follow random drift patterns in zebrafish
Researchers used CRISPR barcoding to track how spermatogonial stem cells (SSCs) contribute to sperm production across a zebrafish's lifetime, finding that clonal dynamics deviate significantly from neutral drift models. The study developed a mathematical framework showing that larger clones tend to drift at higher rates, suggesting non-random selection pressures. These findings have implications for understanding allele transmission and male fertility across the reproductive lifespan.
Researchers identify synthetic lethal TYMS inhibitor effective against ATRX-deficient cells
Scientists developed a phenotype-first screening approach that identified PP12, a covalent fragment that selectively kills ATRX-deficient cells by inhibiting thymidylate synthase (TYMS). The study combines covalent fragment screening, chemoproteomics, and genetic analysis to link drug phenotypes to specific cellular targets. This work establishes a generalizable methodology for discovering synthetic lethal drug candidates in cancer cells with specific genetic deficiencies.